← Russell 3000 cross-section

NEOG NEOGEN CORP

Trailing twelve months to 2026-05-31 · as filed 2026-07-30, not restated
Healthcare

Scale

Market cap
$2.6bn
Revenue TTM
$870m
Net income TTM
$-8m
Free cash flow
$32m
Composite score
38.8
Sector rank
#1490

Valuation

P / E
EV / EBITDA
33.7
EV / sales
3.7
FCF yield
1.23%
Earnings yield vs 10-yr
-5.04pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-0.9%
EBITDA margin
10.9%
ROE
-0.4%
ROIC
-0.8%
Revenue growth
-2.7%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Because of our extensive and longstanding partnerships in the distribution channels, we are optimistic about potential future revenue growth in the segment, particularly as a result of our commercial teams leveraging these partnerships. In fiscal year 2025, restructuring actions in our genomics business led to voluntary revenue attrition, following our strategic shift away from lower margin business. We expect these issues to continue to impact us in fiscal year 2026. 20 Executive Overview Results of Operations Revenues Revenue decreased $9.8 million during the three months ended February 28, 2026 compared to the three months ended February 28, 2025. …NEOGEN CORP, 10-Q, period ended 2026-02-28, filed 2026-04-09

Read the full passage →